©bongkarn thanyakij via Canva.com
Combination Products: FDA's Proposed Rule for GMP Requirements and Introduction and Expectations for "Combo" Products
This Webinar is over| Date | Jul 30, 2014 |
| Time | 12:00 PM EDT |
| Cost | $195.00 |
|
Online
|
Overview:
What is a combination product? What are some examples of combination products? How are combination products assigned for review? Where can I find guidance for how master files can be used in the submission of information relevant to my combination product? Determine which Center will review my combination or non-combination product?
These topics and more will be addressed during this Webinar, including recently FDA's proposed rule to codify the current good manufacturing practice (cGMP) requirements applicable to combination products. This proposed rule is intended to promote the public health by clarifying which cGMP requirements apply when drugs, devices, and biological products are combined to create a combination product. In addition, the proposed rule sets forth a transparent and streamlined regulatory framework for firms to use when demonstrating compliance with cGMP requirements for "single-entity" and "co-packaged" combination products. FDA proposes to create 21 CFR Part 4, subpart A, to codify the cGMP requirements that apply to combination products. What current good manufacturing practice requirements apply to my combination product? The proposed rule seeks to clarify which cGMP requirements apply when drugs, devices, and biological products are used to create combination products. The agency notes that there are no express preemption provisions of the act applicable to prescription drugs or biological products.
Areas covered in the session:
Who will benefit: This webinar will provide valuable assistance and guidance to device companies in involved in commercialization of combination products. Employees who will benefit include:
GlobalCompliancePanel
USA Phone:800-447-9407
Fax: 302-288-6884
webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com
What is a combination product? What are some examples of combination products? How are combination products assigned for review? Where can I find guidance for how master files can be used in the submission of information relevant to my combination product? Determine which Center will review my combination or non-combination product?
These topics and more will be addressed during this Webinar, including recently FDA's proposed rule to codify the current good manufacturing practice (cGMP) requirements applicable to combination products. This proposed rule is intended to promote the public health by clarifying which cGMP requirements apply when drugs, devices, and biological products are combined to create a combination product. In addition, the proposed rule sets forth a transparent and streamlined regulatory framework for firms to use when demonstrating compliance with cGMP requirements for "single-entity" and "co-packaged" combination products. FDA proposes to create 21 CFR Part 4, subpart A, to codify the cGMP requirements that apply to combination products. What current good manufacturing practice requirements apply to my combination product? The proposed rule seeks to clarify which cGMP requirements apply when drugs, devices, and biological products are used to create combination products. The agency notes that there are no express preemption provisions of the act applicable to prescription drugs or biological products.
Areas covered in the session:
- Introduction to Combination Products if you design, develop, produce, distribute and deploying a sustainable regulatory strategy
- Description and explanation of FDA's proposed rule
- Requirements for Single-Entity and Co-Packaged Combination Products
- Identify requirements that apply to the constituent parts of a Combination Product before they are combined, or packaged together
- What current good manufacturing practice requirements apply to my combination product?
- Learn FDA's new terms and phrases
- Understand how to address a Request for Designation for a combination or non-combination product and examples of "combo" products
- Resources and guidance to help define a proven regulatory strategy
Who will benefit: This webinar will provide valuable assistance and guidance to device companies in involved in commercialization of combination products. Employees who will benefit include:
- All levels of management and departmental representatives and those who desire a better understanding or a "refresh" overview
- Regulatory Affairs
- Clinical Affairs
- Quality and Compliance
- Marketing & Sales
- Distributors
- Engineering/Technical Services/Operations
- Consultants
GlobalCompliancePanel
USA Phone:800-447-9407
Fax: 302-288-6884
webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com
Create your own event
Turn your passion into a business.
Turn your passion into a business.